Scholarlink

<p>Despite advances with anti-programmed death (PD)-1-based immunotherapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC), identifying who will benefit from these therapies remains challenging. In a prospective, multicenter study, serum levels of 92 cytokines were measured in pretreatment sera collected on 38 (discovery cohort) and 40 (validation cohort) patients with R/M HNSCC undergoing anti-PD-1-based immunotherapy. A prognostic cytokine score comprised of four cytokines (CXCL1, MCP-4, IL6, CD40) was developed using Cox elastic net modeling within the discovery cohort and showed concordance indices of 0.71 and 0.79 for overall survival (OS) in the discovery and validation cohorts, respectively. High cytokine scores were linked to worse OS (<i>p</i> &lt; 0.01, adjusted HR = 2.07, 95% CI = 1.26–3.41). Further, the cytokine score outperformed established biomarkers including TMB and PD-L1 CPS. Our results suggest that serum cytokine proteomic score may serve as prognostic biomarker for anti-PD-1 therapy in R/M HNSCC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A cytokine-based serum proteomic score is a prognostic biomarker for immunotherapy in head and neck cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月24日

查看全文
  • Md Saiful Islam Saif,
  • Kartik Sehgal,
  • Ze Zhang,
  • Rondi A. Butler,
  • John K. Wiencke,
  • Annette M. Molinaro,
  • Julianna Miller,
  • Hannah G. Stolrow,
  • Keisuke Shirai,
  • Lucas A. Salas,
  • Devin C. Koestler,
  • Robert Haddad,
  • Brock C. Christensen,
  • Karl T. Kelsey

摘要

Despite advances with anti-programmed death (PD)-1-based immunotherapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC), identifying who will benefit from these therapies remains challenging. In a prospective, multicenter study, serum levels of 92 cytokines were measured in pretreatment sera collected on 38 (discovery cohort) and 40 (validation cohort) patients with R/M HNSCC undergoing anti-PD-1-based immunotherapy. A prognostic cytokine score comprised of four cytokines (CXCL1, MCP-4, IL6, CD40) was developed using Cox elastic net modeling within the discovery cohort and showed concordance indices of 0.71 and 0.79 for overall survival (OS) in the discovery and validation cohorts, respectively. High cytokine scores were linked to worse OS (p < 0.01, adjusted HR = 2.07, 95% CI = 1.26–3.41). Further, the cytokine score outperformed established biomarkers including TMB and PD-L1 CPS. Our results suggest that serum cytokine proteomic score may serve as prognostic biomarker for anti-PD-1 therapy in R/M HNSCC.